Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Fineline Cube Dec 20, 2025
Policy / Regulatory

NMPA Extends Validation Period for COVID-19 Antigen Detection Reagents

Fineline Cube Dec 9, 2022

The National Medical Products Administration released a notification extending the validation period of approvals for...

Company Deals

Science Standard Medical Testing Raises Pre-Series A Funding

Fineline Cube Dec 9, 2022

Science Standard Medical Testing, a professional third-party testing institution based in Changzhou, reportedly raised “tens...

Company Deals

Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199

Fineline Cube Dec 9, 2022

Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...

Company Deals

XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development

Fineline Cube Dec 9, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai...

Company Drug

Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma

Fineline Cube Dec 9, 2022

Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...

Company Deals

Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer

Fineline Cube Dec 9, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu...

Company Deals

Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech

Fineline Cube Dec 9, 2022

Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...

Company Deals

ExoNeuglia Secures Angel Funding for iPSC-Based Cell Therapy

Fineline Cube Dec 8, 2022

ExoNeuglia, a stem-cell-focused biotech based in Suzhou, reportedly raised “tens of millions” of renminbi in...

Company Drug

Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation

Fineline Cube Dec 8, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s...

Company Drug

CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials

Fineline Cube Dec 8, 2022

China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...

Policy / Regulatory

24 Provinces Form Alliances for Volume-Based Procurement of Medical Consumables

Fineline Cube Dec 8, 2022

The Henan provincial alliance procurement office released a notification indicating that 24 provinces/regions will form...

Company Deals

Yuanmai Cell Biotechnology Secures Angel Funding for Macrophage Immunotherapy

Fineline Cube Dec 8, 2022

Yuanmai Cell Biotechnology Co., Ltd, a macrophage immunotherapy developer based in Nanjing, reportedly raised “tens...

Company Deals

Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics

Fineline Cube Dec 8, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the...

Company Deals

Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform

Fineline Cube Dec 8, 2022

Shanghai Hantong Medical Technology Co., Ltd reportedly raised “tens of millions” of renminbi in an...

Company Deals

GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development

Fineline Cube Dec 8, 2022

China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised...

Company Drug

Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...

Company Drug

NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...

Company Drug

SciClone’s Danyelza Approved for Marketing in China by NMPA

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...

Company Drug

Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study

Fineline Cube Dec 8, 2022

AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...

Company Deals

Shaanxi Panlong Pharma Partners with Porton Pharma Solutions for Drug Development

Fineline Cube Dec 7, 2022

China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) announced a technology commission (development) agreement...

Posts pagination

1 … 523 524 525 … 600

Recent updates

  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
  • Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.